Circulating tumor DNA (ctDNA) testing can identify molecular residual disease in patients with colorectal cancer who have no radiographic evidence of cancer following curative-intent treatment. Although its prognostic value is well established, questions remain about how best to use the results to guide treatment.
Researchers in Mexico evaluated a machine-learning approach that uses targeted RNA sequencing to classify B-cell acute lymphoblastic leukemia into molecular subtypes—potentially offering a more accessible alternative to approaches that rely on whole-transcriptome sequencing.
Understanding the biology of ctDNA and matching testing methods to specific clinical needs will be essential to the use of liquid biopsies in cancer care, particularly as these tests become more sensitive, according to experts.
The Somatic Profiling for Pediatric Cancer: Refining Our Understanding and Treatment (SPROUT) Working Group developed consensus recommendations to help clinicians determine which molecular tests to order for children, adolescents, and young adults with solid tumors.